First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced <i>EGFR</i> -mutated NSCLC: a meta-analysis of randomized phase III trials-Reference-Cited by-同舟云学术

First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials

Published:2024-06-03 Issue:8 Volume:24 Page:775-780
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Landre Thierry¹,Assié Jean-Baptiste²³⁴,Chouahnia Kader⁵,Des Guetz Gaetan⁶,Auliac Jean-Bernard²,Chouaïd Christos²⁷^ORCID

Affiliation:

1. Unité d’Oncologie et Gériatrie, HUPSSD, Hôpital René Muret, AP-HP, Sevran, France

2. Department of Pneumology, Centre Hospitalier Intercommunal de Créteil, Créteil, France

3. Université de Paris-Est Créteil, Créteil, France

4. Functional Genomics of Solid Tumors Laboratory, Centre de Recherche des Cordeliers, Inserm, Sorbonne Université, Université Paris Cité, Paris, France

5. Servie d’Oncologie, HUPSSD, Hôpital Avicenne, AP-HP, Bobigny, France

6. Service d’Oncologie, Centre Hospitalier Delafontaine, Saint-Denis, France

7. Inserm U955, UPEC, IMRB, Créteil, France

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2024.2362889

Reference23 articles.

1. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

2. Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes

3. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib

4. Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study

5. Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial